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Buerger’s disease, which is also referred to by its
pathologic description of thromboangiitis obliterans
(TAO), is now widely recognized as a specific disease
entity that is characterized by the onset of distal
extremity ischemic symptoms at an early age in the
absence of an underlying proximal embolic source,
trauma, autoimmune disease, diabetes, or hyperlipi-
demia.1 Although Buerger’s disease is worldwide in its
distribution, it is far more prevalent in the middle, near,
and far east regions than in North America.2 It occurs
predominantly in men, but recent evidence indicates
that the incidence rate in women is increasing.3
Virtually all of the patients are heavy users of tobacco,
usually cigarettes. The disease generally is seen first
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Purpose: Thromboangiitis obliterans (TAO), or Buerger’s disease, a distinct form of vascu-
lar occlusive disease that afflicts the peripheral arteries of young smokers, is often charac-
terized by an inexorable downhill course even in patients who discontinue smoking once a
stage of critical limb ischemia associated with ulceration or gangrene is reached. As part of
a phase I clinical trial to document the safety and efficacy of intramuscular gene transfer
of naked plasmid DNA-encoding vascular endothelial growth factor (phVEGF165) in the
treatment of critical limb ischemia, we treated TAO in 6 patients.
Methods: Seven limbs in 6 patients (3 men, 3 women; mean age, 33 years; range, 33 to
51 years) who satisfied the criteria for TAO and had signs or symptoms of critical limb
ischemia were treated twice, 4 weeks apart, with 2 or 4 mg of phVEGF165, which was
administered by direct intramuscular injection at 4 arbitrarily selected sites in the
ischemic limb. The gene expression was documented by enzyme-linked immunosorbent
assay that was performed on peripheral blood samples.
Results: The ulcers that were nonhealing for more than 1 month healed completely in 3
of 5 limbs after the intramuscular phVEGF165 gene therapy. Nocturnal rest pain was
relieved in the remaining 2 patients, although both continue to have claudication. The
evidence of the improved perfusion to the distal ischemic limb included an increase of
more than 0.1 in the ankle brachial index in 3 limbs, an improved flow shown with mag-
netic resonance imaging in 7 of the 7 limbs, and newly visible collateral vessels shown
with serial contrast angiography in 7 of the 7 limbs. The adverse consequences of the
phVEGF165 gene tranfer were limited to transient ankle or calf edema in 3 of the 7
limbs. Two patients with advanced distal forefoot gangrene ultimately required below-
knee amputation despite the evidence of improved perfusion. A histologic section dis-
closed the classic pathologic findings of TAO.
Conclusion: Therapeutic angiogenesis with phVEGF165 gene transfer, if instituted before
the development of forefoot gangrene, may provide a novel therapy for patients with
advanced Buerger’s disease that is unresponsive to standard medical or surgical treat-
ment methods. (J Vasc Surg 1998;28:964-75.)
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with claudication (often at the foot level) but, if ciga-
rette smoking continues, often progresses to critical
limb ischemia with dependent rubor, trophic changes,
and ultimately digital gangrene or gangrenous ulcers.
Clinical experience has shown that if the disease is
diagnosed before the onset of gangrene or tissue loss,
then patients with Buerger’s disease can be assured
that the complete cessation of tobacco use will gener-
ally result in a benign course with the avoidance of
future amputation.2 On the other hand, all other
forms of therapy, including the use of prostaglandins,
anticoagulant or thrombolytic therapy, and surgical
reconstruction, are palliative and often unsuccessful in
the setting of continued smoking. Surgical revascular-
ization, in particular, does not usually produce a
durable result because of the diffuse distal nature of the
obstructing lesions in Buerger’s disease. Most patients,
in fact, are not candidates for reconstruction because a
distal target vessel for bypass grafting cannot be iden-
tified. Inada et al,4 for example, found that only 4.6%
of 236 patients could be treated by surgical means.
Preclinical studies have shown that angiogenic
growth factors can stimulate the development of col-
lateral arteries in animal models of peripheral and
myocardial ischemia—a concept now referred to as
therapeutic angiogenesis.5-8 Vascular endothelial
growth factor (VEGF), also known as vascular per-
meability factor, is a secreted endothelial cell–specific
mitogen that has been shown to be particularly effec-
tive in these studies because of its high affinity bind-
ing to endothelial cells (the most critical cellular ele-
ment responsible for new vessel formation).6 For the
past 18 months, we have been conducting a phase I
clinical trial to document the safety and efficacy of
the use of intramuscular gene transfer of naked plas-
mid DNA-encoding for the 165 amino acid isoform
of VEGF (phVEFG165) in patients with critical limb
ischemia. As part of that study, 6 patients (7 limbs)
who met the criteria for TAO have undergone treat-
ment, and this forms the basis of this report.
METHODS
Patients. Six patients of the first 22 who enrolled
in a phase I nonrandomized study to document the
safety of intramuscular phVEGF165 gene transfer met
the following diagnostic criteria for Buerger’s disease:
the onset of distal extremity ischemic symptoms
before the age of 50 years; the absence of an underly-
ing proximal embolic source, trauma, autoimmune
disease, diabetes, or hyperlipidemia; healthy arteries
proximal to the distal superficial femoral artery seg-
ment; and distal occlusive disease with distinctive arte-
riographic or pathologic findings.
The patients were considered to be candidates for
intramuscular gene therapy if they met the following
criteria: (1) the patients had chronic critical limb
ischemia, including rest pain or nonhealing ischemic
ulcers, that was present for a minimum of 4 weeks
without evidence of improvement in response to con-
ventional therapy; and (2) the patients were not candi-
dates for either surgical or percutaneous revasculariza-
tion procedures. In addition, objective documentation
of ischemia, including a resting ankle brachial index
(ABI) of less than 0.6 or a toe brachial index (TBI) of
less than 0.5, in the affected limb on 2 consecutive
examinations performed 1 week apart was necessary.
The criteria that were used to document a change in
limb status were adopted from the standards recom-
mended by The Society of Vascular Surgery/North
America Chapter of the International Society of
Cardiovascular Surgery. This study was a phase I non-
randomized trial designed to document the safety of
intramuscular phVEGF165 gene transfer and to moni-
tor patients for evidence of bioactivity. The design was
approved by the US Food and Drug Administration,
the Recombinant DNA Advisory Committee of The
National Institutes of Health, and the Human
Institutional Review Board and Institutional Biosafety
Committee of St Elizabeth’s Medical Center.
Plasmid DNA (phVEGF165). Each patient
received an intramuscular injection of a eukaryotic
expression vector that encoded the VEGF165 gene
whose transcription was regulated by cytomegalovirus
promoter/enhancer. The preparation and purifi-
cation of the plasmid from cultures of phVEGF165-
transformed Escherichia coli was performed in the
human gene therapy laboratory at St Elizabeth’s
Medical Center with the column method (Qiagen
Mega Kit, Qiagen, Inc, Valencia, Calif). The purified
plasmid was stored in vials and pooled for quality-
controlled analyses.
Intramuscular phVEGF165 gene transfer.
Aliquots of 500 m g of VEGF165 plasmid DNA were
diluted in a sterile saline solution, and 4 aliquots
(total of 2000 m g) were administered into the calf or
distal thigh muscles of the patients by direct intra-
muscular injection into the ischemic limb. The injec-
tion sites were selected arbitrarily according to the
available muscle mass and included sites above and
below the knee. The volume of each of the 4 injec-
tions per limb progressively was increased during the
course of the study from 0.5 mL to 3 mL to 5 mL.
Four weeks after the first 2000-m g injection, a sec-
ond 2000-m g injection was administered for a total
of 4000 m g of plasmid DNA per patient.
Patient follow-up and assessment. The patients
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were followed weekly on an outpatient basis during
the first 8 weeks after the initial gene therapy proce-
dure and then at monthly intervals thereafter.
Ischemic ulcers were documented with color photog-
raphy. The patients received analgesics as necessary for
the management of rest pain, and their requirements
were carefully documented. Ischemic ulcers and
necrotic lesions were managed in a standard fashion,
and antibiotics were prescribed as necessary. No spe-
cial forms of therapy or bed rest were used during the
study period. The resting ankle brachial index and the
toe brachial index were calculated with the quotient
of absolute or toe pressure to brachial pressure.
Intraarterial digital subtraction angiography and mag-
netic resonance angiography were performed at 1
week before and 4 weeks after each treatment and at
3 months after the latter of the 2 intramuscular injec-
tions. Digital subtraction angiography was performed
as a selective single-leg runoff study with undiluted
nonionic contrast media (Isoview 370, Squibb
Diagnostics, New Brunswick, NJ). A minimum of 2
images (early and late frames) at the thigh, knee, calf,
and foot levels were recorded with digital acquisition
and hard copies in a 35 · 45–cm format. To allow a
precise comparison between the angiograms that were
obtained before and after the gene therapy, meticu-
lous attention was paid to the volume of contrast used
and to the timing of the image acquisition to be cer-
tain that the comparison of identical phases was pos-
sible. The diameter of the newly visible collateral ves-
sels was documented by the comparison with a 0.9-in
diameter reference wire that was taped to the skin.
Magnetic resonance angiography was performed
with a 1.0-T superconducting system (Impact, Seimens,
Erlanger, Germany) by means of a transmit/receive
extremity coil, a body coil, or both and by means of
commercially available 2-dimensional time-of-flight
noncontrast-enhanced pulse sequences. The overlap-
ping 2-dimensional  time-of-flight sequences were
obtained, at levels that were standardized for each
patient, from the malleoli to the pelvis. The maximal
intensity projections were obtained at 60-degree inter-
vals and were used to compare the pretherapy and post-
therapy studies. An increase in the number of visible ves-
sels or an increase in the intensity or apparent size of a
previously visible vessel was considered improvement.
Serum vascular endothelial growth factor lev-
els. Enzyme-linked immunosorbent (ELISA) assays
were performed at baseline and weekly for up to 12
weeks after the initial treatment to detect evidence
of gene expression at the protein level. The samples
were centrifuged immediately for 20 minutes at
3600 rpm at 4°C, and the serum was stored at 20°C
until analysis. The serum VEGF was determined
with immunoassay according to the manufacturer’s
instructions (R & D Systems, Minneapolis, Minn).
The results were compared with a standard curve of
human VEGF with a lower detection limit of 5
pg/mL. The samples were checked with serial dilu-
tion, which was performed at least in duplicate.
RESULTS
The demographic and clinical data for the 4 men
and 2 women (aged 20 to 48 years at the onset of
Table I. Clinical features of 6 patients (7 limbs)
Patient characteristics Clinical findings DSA/MRA
Follow-up
No. Age (years) Sex Previous treatment (months) Before Gtx After Gtx Before Gtx After Gtx
1 33 F 4 bypass grafts (occluded) 18 toe gangrene healing of gangrene SFA occlusion plus new 
and prostaglandin collaterals
therapy
2 39 F sympathectomy 17 forefoot gangrene BKA SFA, POP plus new 
occlusion collaterals
3 39 F sympathectomy 14 toe gangrene, toe amputation, AT, PT, PN plus new 
heel ulcer limb salvage occlusion collaterals
4 44 M 3 bypass grafts (occluded) 12 forefoot gangrene BKA SFA, POP plus new 
and prostaglandin occlusion collaterals
therapy
5 51 M narcotic analgesics 12 rest pain walking of 5 minutes SFA occlusion plus new 
without pain collaterals
6 26 M prostaglandin therapy 7 toe gangrene healing of gangrene AT, PT, PN plus new 
occlusion collaterals
7 46 M none 3 toe gangrene improvement of AT, PT, PN plus new 
gangrene occlusion collaterals
DSA, Digital subtraction angiography; MRA, magnetic resonance angiography; Gtx, gene therapy; SFA, superficial femoral artery; BKA,
below-knee amputation; POP, popliteal; AT, anteriortibial; PT, posterior tibial; PN, peroneal.
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symptoms) are shown in Table I. All the patients had
been heavy smokers for many years, and, in fact, 3
patients (4 of 7 limbs treated) had been unable to
stop smoking before the initiation of the gene ther-
apy treatment and indeed, despite counseling, con-
tinued to smoke during the study period (Table II).
The 3 patients who quit did so more than 6 months
before being referred to us for gene therapy.
Previous medical or surgical treatment included
multiple distal bypass grafts in 2 patients (all of
which were occluded), prostaglandin therapy in 3
patients, and sympathectomy in 2 limbs in 1 patient.
At the time of the assessment for gene therapy,
necrotic lesions were present in 6 of 7 limbs. These
lesions included toe gangrene in 4 limbs and the
involvement of the forefoot in 2 limbs. One patient
was seen with severe rest pain only. Upper extremity
involvement in the form of Raynaud’s phenomenon
was present in 3 patients, and thrombophlebitis
could be documented in 1 patient.
The average length of follow-up time at the time of
this report was 14 months (range, 3 to 18 months).
The intramuscular gene transfer into the ischemic limb
induced minimal local discomfort for up to 72 hours
after the injection. The serial creatinine phosphokinase
measurements remained in the normal range. No sys-
temic or local inflammatory reactions were noted. No
antibodies to VEGF were developed in patients. To
date, a careful follow-up evaluation has documented
no change in visual acuity and no funduscopic evi-
dence of diabetic retinopathy. Furthermore, no evi-
dence of latent neoplasm has been observed. The only
complication seen has been transient lower extremity
edema in 3 limbs that was consistent with the VEGF
enhancement of vascular permeability.9
Transgenic expression. The blood levels of
VEGF transiently peaked between 1 and 3 weeks
after the gene transfer as illustrated in the weekly
serum ELISA assays (Table III). Eleven out of the
total of 14 phVEGF165 treatments (injections) were
associated with an increase followed by a decrease in
level of VEGF protein in the serum. Thus, although
individual values vary a great deal, a typical pattern
is seen in most patients after injection. The presence
of peripheral edema in 3 patients occurring mainly in
the treated limb also provides indirect evidence of
VEGF expression and corresponded in time to the
rise in serum VEGF levels.
Hemodynamic studies. Five of the 7 limbs had
an ABI of less than 0.6 before the gene therapy.
After the gene therapy, the ABI increased in 4 of
these 5 limbs by more than 0.1 (mean increase,
0.25). The 2 limbs with ABIs of more than 0.6 had
TBIs of less than 0.5, and in both instances, after the
gene therapy, the TBI increased. The ABIs measured
simultaneously in the contralateral limb at each time
point were abnormal, which implied bilateral disease
in 4 of the 7 limbs, but remained unchanged during
the treatment period (Table IV). Toe plethysmogra-
phy was performed where possible, and an example
of the restoration of a pulsatile waveform seen 4
weeks after the gene therapy is illustrated in Fig 1.
These improvements in hemodynamic pressure
indices were sustained during the followup period
but did not dramatically change after the second
injection. Only 2 of the 6 patients were able to walk
sufficiently to undergo graded treadmill testing
before the gene therapy. Both of these patients had
an improvement in their walking distance that was
documented by follow-up treadmill testing 8 weeks
after their treatment. 
Angiographic studies. Digital subtraction an-
giography before the gene therapy documented the
typical findings of Buerger’s disease in all 7 limbs
(Fig 2). These findings included segmental occlusive
disease involving primarily the tibial and digital ves-
sels but extending up to the distal superficial femoral
Fig 1. Toe plethysmographic tracings taken from a
patient immediately before and 4 weeks after initial treat-
ment with VEGF165 gene therapy.
Table II. History of smoking
Change of
Amount of smoking
smoking Cessation of habits
Patient Age (cigarettes/day) smoking during Gtx
1 33 30 yes(12 months before Gtx) no
2 39 10 no no
3 39 10 no no
4 44 40 no no
5 51 20 no no
6 26 12 yes(5 months before Gtx) no
7 46 30 yes(6 months before Gtx) no
Gtx, Gene therapy.
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artery or the popliteal artery in 4 limbs. Typical
corkscrew collaterals were observed, and vessels
proximal to the distal superficial femoral artery were
notably free of any evidence of disease. After the
gene therapy, new collateral vessels that ranged in
size from 200 to 800 m m in diameter were observed
(Fig 2). The serial magnetic resonance angiograms
of the ischemic limb showed qualitative evidence of
improved distal flow in all instances, which included
increased signal intensity in previously identified ves-
sels and an increase in the number of vessels that
were visible (Fig 3). 
Clinical outcome. Overall, clinical improvement
was observed in 5 of the 7 limbs that were treated by
VEGF165 gene therapy, whereas the 2 limbs that were
seen with forefoot gangrene ultimately necessitated
amputation at the below-knee level. In addition, toe
amputation with limb salvage was achieved in 1 limb.
The healing of toe gangrene and the resolution of rest
pain was achieved in 3 limbs (Fig 4), and improved
walking distance was documented in 2. In general,
the clinical improvement correlated with the improve-
ment of hemodynamic status, although 1 of the
patients ultimately required below-knee amputation
despite an improvement of 0.27 in the ABI. Of inter-
est, the improvement in clinical status occurred in 2
limbs despite the documentation of failure to discon-
tinue smoking in both of those patients.
Pathology. The histologic findings in the
pathologic specimen that was obtained from 1 of the
patients who underwent amputation are illustrated
in Fig 5 and show the typical findings of Buerger’s
Table III. Vascular endothelial growth factor serum levels
VEFG serum levels (pg/mL)
Patient no. Before first Gtx At first peak After first Gtx At second peak After second Gtx
1 47 223 116 607 0
2 ND 59 29 888 30
3 142 24 31 37 20
4 34 668 ND 550 69
5 151 251 69 347 67
6 20 43 18 147 13
7 ND 264 53 46 47
VEFG, Vascular endothelial growth factor; Gtx, gene therapy; ND, not performed.
Fig 2. Digital subtraction angiogram from a patient before gene therapy showing typical find-
ings of Buerger’s disease at distal popliteal and tibial levels with normal femoral vessel proximal-
ly. Angiogram after gene therapy at 8 weeks shows significant increase in collateral formation.
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disease. Numerous small blood vessels—both arteri-
al and venous—that were occluded by partially
recanalized thrombus and were surrounded by an
extensive inflammatory cell infiltrate are evident.
DISCUSSION
The first detailed description of a patient who
was seen with the condition now known as TAO was
described by Felix von Winiwarter in 1879.10 In
1908, Leo Buerger11 fully characterized this disease
entity in a detailed pathologic study of 11 amputat-
ed limbs and, in fact, suggested the term throm-
boangiitis obliterans to distinguish it from athero-
sclerosis. During the first half of the 20th century,
there was a tendency for the disease to be overdiag-
nosed, which lead to skepticism as to its actual exis-
tence.1 At present, however, this controversy seems
resolved, and there now is abundant evidence of the
existence of this pecular form of occlusive disease
that afflicts the peripheral arteries of young smok-
ers.12 Because its specificity is primarily on the basis
of its clinical characteristics, the disease is perhaps
best termed Buerger’s disease rather than TOA, as
suggested by Shionoya.1
All 6 patients who were described here were seen
by us with the typical features of Buerger’s disease.
In each case, the age at onset was less than 50 years
(mean, 32.5 years; range, 20 to 48 years), and each
gave a history of heavy cigarette usage. None of the
4 males and 2 females in this study were diabetic nor
Fig 3. Magnetic resonance angiograms without intravenous contrast medium from a patient
before and after gene therapy illustrating both increased number of collateral vessels and
increased signal intensity in previously identified vessels.
Table IV. Ankle brachial indices of 6 patients (7 limbs)
Ankle brachial index
1 month 2 months 3 months 
Patient no. Age(years) Limb Baseline after Gtx after Gtx after Gtx
1 33 treated 0.3 0.42 0.51 0.64
untreated 0.95 1 0.99 0.93
2 39 treated 0 0.24 0.25 0.27
untreated 0.35 0.33 0.34 0.31
3 39 treated 0.31 0.39 0.55 0.54
untreated NA NA NA NA
4 44 treated 0.39 0.31 0.37 0.32
untreated 0.64 0.69 0.68 0.63
5 51 treated 0.55 0.61 0.65 0.7
untreated 1.00+ 1.0+ 1.00+ 1.00+
6 26 treated 0.77 0.72 0.8 0.72
untreated 1.00+ 1.0+ 1.00+ 1.00+
7 46 treated 0.7 0.81 0.8 0.75
untreated 0.75 0.84 0.83 0.81
Gtx, Gene therapy; NA, not performed.
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were any seen with features of atherosclerosis oblit-
erans. All the patients were carefully evaluated for
evidence of a hypercoagulable state or autoimmune
forms of vasculitis, and the laboratory investigations,
which included testing for antithrombin 3, protein
C, protein S, circulating lupus anticoagulants, anti-
nuclear antibiodies, rheumatoid factors, and anticen-
tromere antibiodies, were negative. Evidence of
hypercholesterolemia and hyperhomocystinemia
also were excluded. No source of systemic emboliza-
tion could be documented with cardiac ultrasound
scan or with abdominal computed tomographic
evaluation. Upper limb involvement characterized
by Raynaud’s phenomenon was noted in 3 patients,
and a history of superficial thrombophlebitis was
present in 1.
All patients were seen with advanced critical limb
ischemia with necrotic lesions present in the toes in
Fig 5. Representative histologic sections of tissue retrieved from a patient with Buerger’s disease
at time of limb amputation. Serial sections stained with elastic tissue trichrome (left) and hema-
toxylin and eosin (middle) show small arteries and veins containing thrombus and surrounded by
significant inflammatory cell infiltrate. Note preservation of normal blood vessel architecture.
Photomicrograph on right is a higher magnification of area indicated in middle photo.
Fig 4. Photographs of feet of 2 patients showing healing of necrotic lesions of toes 6 to 8
weeks after initiation of gene therapy with phVEGF165.
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4 limbs and with forefoot gangrene present in 2
limbs. Only 1 patient in this series was seen with rest
pain only. The patients first were seen by us an aver-
age of 7 years after the onset of their symptoms and
had critical ischemia that included gangrenous
lesions of the feet for an average of 5 months.
Previous treatment had included multiple attempts
at distal bypass grafting procedures in 2 patients,
bilateral sympathectomy in 1 patient, and prosta-
glandin therapy in 3 patients. Three patients claimed
to have stopped smoking completely more than 6
months before the referral for gene therapy, and 3
others had not been able to do so.
Thus, the patients who are described here repre-
sent a small subgroup of Buerger’s disease that was
first seen at a relatively late stage after having failed
conservative therapy and more aggressive interven-
tional therapy that included distal bypass graft
surgery. Indeed, in the case of the first 4 limbs that
were treated in this study, the patient had been
advised to undergo amputation below the knee by
the treating physician and had refused, and patients
5 to 7 were told they might require amputation if
their limbs did not respond to conservative treat-
ment. As such, they met the strict inclusive criteria
for entry into this phase I clinical trial of intramus-
cular gene therapy with phVEGF165. Indeed,
patients 1 and 2 who are presented here were among
the first 9 patients to enter this trial and are also
included in the recently published report of
Baumgartner et al.13
Because VEGF had not been previously adminis-
tered clinically either as a recombinant protein or by
means of gene transfer, this clinical trial was designed
primarily to assess the safety of intramuscular gene
therapy with phVEGF165 and, in addition, to detect
evidence of bioactivity in the form of both evidence
of gene expression at the protein level and in terms of
clinical efficacy.
From the perspective of patient safety, no signifi-
cant adverse effects were observed in this group of
patients. Aside from some minor discomfort at the
injection sites and peripheral edema in 3 of the 7
limbs, no other side effects were observed and, specif-
ically, there was no evidence on long-term follow-up
of any systemic effects of VEGF in terms of the devel-
opment of retinopathy or new tumor growth.
The analysis of gene expression at the protein
level by the use of an ELISA assay for VEGF docu-
mented considerable variability from patient to
patient. Although the serial VEGF levels in the indi-
vidual patients tended to peak at 1 to 3 weeks after
gene transfer, the degree of elevation was highly
variable and did not necessarily correlate with the
clinical outcome or the hemodynamic change. This
may be partly because the measurements were only
taken weekly, and thus, some peak values may have
been missed. At any rate, the use of VEGF levels on
the basis of these data remains to be clarified.
Similarly, we interpret the development of peripher-
al edema in some patients as evidence of VEGF
expression given that enhanced vascular permeabili-
ty is a feature of VEGF.14 Whereas we have docu-
mented in a previous analysis that the development
of edema corresponds temporally with increased
VEGF levels and is consistent with the time course
of gene expression (3 to 21 days) that was estab-
lished in animal studies, this finding was not a pre-
dictor of clinical improvement.15
The analysis of the clinical outcomes that were
observed in these patients and the hemodynamic and
imaging data may be cautiously interpreted as provid-
ing preliminary evidence of the potential efficacy of
intramuscular VEGF gene therapy. Specifically, the
ABI, or in 2 instances the TBI, increased by at least 0.1
in 4 of the 7 limbs, and, at the same time, no change
was documented in the contralateral limbs. This was
accompanied by the restoration of pulsatile flow in the
toe pulse volume recordings as well. Clinically, rest
pain was relieved and necrotic ulcers healed in all but
2 limbs—both of which ultimately went on to below-
knee amputation at 3 and 7 months after gene thera-
py. This occurred despite an improvement in the
hemodynamic studies because of advanced gangrene
of the forefoot, which had been present for 4 and 5
months, respectively, before the gene therapy. The 1
patient who was seen with only rest pain not only
experienced relief of the rest pain but also improve-
ment in the claudication walking distance. Magnetic
resonance angiography showed an increased flow to
the calf vessels in all 7 limbs. Contrast angiography
showed evidence of increased collaterals in all 7 limbs
but probably underestimated the degree of collateral
development; the size of the newly formed vessels in
most instances is less than the resolution of standard
contrast angiographic techniques.16
The conceptual basis for therapeutic angiogene-
sis with phVEGF165 gene transfer was developed on
the basis of studies from our laboratory and others.
Work from several laboratories17-20 has convincingly
shown evidence of transgenic expression after the
direct injection of nonviral covalently closed plasmid
DNA into skeletal muscle. Whereas the transfection
efficiency with naked DNA is known to be relatively
low, particularly in comparison with plasmids that
use viral vectors, the clinical outcomes here suggest
that the success of gene therapy is not solely a func-
tion of transfection efficiency. Because VEGF is
actively secreted by intact cells, studies from our lab-
oratory21 have shown that meaningful biologic out-
comes may be possible as a result of the paracrine
effects of this secreted gene product. Furthermore,
VEGF-induced angiogenesis in preclinical studies
has been documented to be site specific and appears
to occur predominantly at the sites of ischemia.22
This again appears to result from the paracrine up
regulation of the principle high-affinity VEGF
receptor Kdr in response to factors released from
hypoxic skeletal myocytes.21 Thus, the presence of
hypoxic muscle in these severely ischemic limbs may
have enhanced the ability of the VEGF produced to
stimulate angiogenesis in this setting. The finding of
peripheral edema in the contralateral limb in some
patients, on the other hand, may imply that this
action of VEGF is not mediated exclusively by the
same receptor.
The patients with Buerger’s disease often appear
with angiography to have abundant collateral vessels
around the multiple distal occlusive lesions, yet the
distal tissue perfusion may be extremely poor, which
leads to advanced necrotic lesions as were seen in this
series. Previous studies from our laboratory23 have
shown that in addition to the ability of VEGF to stim-
ulate new collateral formation, it is also capable of
improving disturbed endothelium-dependent flow in
collaterally perfused limbs. It is entirely possible that
the improved flow that was seen with magnetic reso-
nance angiography in these patients was at least, in
part, the result of enhanced endothelium-dependent
blood flow in the already present collateral vessels.
Patients with Buerger’s disease by definition tend
to be relatively young and free of evidence of diffuse
atherosclerosis in their native arteries. Recent studies
from our laboratory have shown that collateral ves-
sel development is impaired as a function of age,24
hypercholesterolemia,25 and diabetes.26 Thus, this
group of patients who are younger and nondiabetic
with normal cholesterol levels may indeed represent
the ideal candidates for angiogenic therapy.
In summary, this report documents the results in 6
patients who met the clinical criteria for Buerger’s dis-
ease who were treated with intramuscular phVEGF165
gene therapy as a part of a larger clinical trial of this
therapy in patients with advanced peripheral vascular
disease who could not be treated surgically or percuta-
neously. These preliminary results document aug-
mented perfusion in all the limbs treated that was suf-
ficient to bring about the healing of gangrenous ulcers
or toes in 4 limbs and to relieve the rest pain in all but
2. The requirement for amputation in the 2 limbs that
were seen with already established necrotic lesions of
the forefoot suggests that gene therapy, to be success-
ful, must be instituted earlier in such cases. The thera-
py for patients with Buerger’s disease who are seen
with advanced critical limb ischemia has generally been
futile with a high risk of amputation, especially in those
patients who continue to smoke. Fiessinger and
Schafer,27 however, reported good results in such
patients with 6-hour daily infusions of Iloprost (a
prostaglandin analog; Berlex, Montville, NJ) given
over a 28-day period. Aside from the complexity and
cost of such a treatment protocol, however, Iloprost is
not currently available in the United States.
Although the data that were presented here are
preliminary and nonrandomized, we believe the data
support the further investigation of therapeutic
angiogenesis in patients with Buerger’s disease who
are seen with critical limb ischemia that is unrespon-
sive to other therapeutic methods.
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Dr Anton N. Sidawy (Washington, DC). Vascular
endothelial growth factor, VEGF, is a peptide growth fac-
tor that causes endothelial cell proliferation. VEGF has
been found to promote the growth of new blood vessels
in the myocardium and peripheral circulation. VEGF
exerts its effects via 2 types of receptors located on the vas-
cular endothelium and is found in various isomers that
defer in their isoelectric charge and their affinity to
heparin. VEGF DNA can be introduced either by using an
adenovirus vector or by injecting a naked plasmid DNA,
encoding the 165 amino acid VEGF isoform. Both have
been shown to produce formation of new blood vessels
experimentally.
Dr Symes and his colleagues ought to be congratulat-
ed on being in the forefront in studying this important
and promising molecule experimentally and clinically. He
reported on the treatment of 6 patients with Buerger’s dis-
ease. As you all know, this disease is difficult to manage in
its late stages. The authors report encouraging results in
limb salvage with VEGF in these patients. I have the fol-
lowing questions for Dr Symes.
Would you expand on the difference between intro-
ducing the naked DNA and introducing the DNA by
means of adenovirus vector? I have heard your group
reporting on injecting naked DNA and I was intrigued by
the results.
Did you perform any evaluation to detect tumors,
especially cancers, that the patients may have had at the
time of treatment? Angiogenesis is a process used by
tumors to gain blood supply from surrounding tissues so
that they will grow. Are you helping that process by inject-
ing VEGF DNA?
As we know from randomized trials, when treating
patients with foot ulcers, about 30% or more of the place-
bo group patients have ulcers that heal. This is probably as
a result of the extra care they receive while in the study.
Your study is a nonrandomized safety study, so there was
no control group for comparison. Would you comment on
the possible bias involved and whether the results you have
obtained are as a result of the extra care that these patients
were given?
Also, please comment on smoking in these patients. In
your study, 3 of 6 patients stopped smoking. Are the
patients who ended up with amputations the ones who did
not stop smoking?
You stated that you injected the material in both limbs
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in patients with bilateral disease. Why is this necessary
because DNA is causing increased VEGF levels in the
blood and should influence both extremities? Why must
the material be injected directly in the affected limb?
I would like to thank the Society for the privilege of
discussing this paper.
Dr James F. Symes. Thank you for your kind com-
ments and for your insightful questions.
First, with regard to our use of naked DNA versus that
incorporating an adenoviral vector, it is well documented
experimentally that incorporation of an adenoviral vector
into any plasmid used for gene therapy will enhance its
transfection efficiency.
On the other hand, adenoviral vectors may have
exposed patients to side effects related to the use of the
viruses themselves. So, it was primarily from the point of
view of safety that we chose to use naked DNA rather than
DNA with a viral vector.
Furthermore, as I indicated, we believe that certain fea-
tures of VEGF allow it to be biologically effective, even
though we used naked DNA. However, if one can show that
adenoviral vectors are indeed safe, I expect that most studies
done with gene transfer will probably incorporate them.
As far as looking for tumors, all of our patients were
meticulously screened with head, thorax, and abdominal
computed tomographic scans before being admitted into
the study.
We also have looked for evidence of tumor appearance
after surgery and, at least to this point, have not seen any
evidence that the VEGF has caused problems in this
regard. Further, we think one of the potential advantages
of using gene therapy as opposed to the administration of
the protein is that you get a relatively low systemic level of
the protein with gene therapy but for a longer period of
time (2 or 3 weeks), and hopefully that might be safer
than if you administered the protein intravenously or
intramuscularly at higher dose levels.
Your question about spontaneous healing of the ulcers
is a good one. It would require a randomized study to be
absolutely certain that some of these ulcers would not
have healed if the patient had received some sort of place-
bo. However, I can tell you that, at least up to the point
that these patients were seen by us, all attempts by the
physicians treating them before our gene therapy trial had
been unsuccessful in healing these ulcers. In addition, the
majority of patients who do not respond to gene therapy
end up with an amputation.
Of the 3 patients who did not stop smoking, 1 did
indeed go on to below-knee amputation, 1 presented with
rest pain only and his rest pain was relieved by gene ther-
apy despite the fact that he did not stop smoking, and the
third patient healed his toe ulcer. Thus, 2 of the 3 people
who kept on smoking, albeit at a reduced rate, did
improve with gene therapy.
With regard to bilateral disease, we did not treat the 2
limbs in that patient at the same time. She was seen ini-
tially with advanced gangrene of 1 forefoot, received gene
therapy for that limb, but ended up with a BK amputation.
She is one of the patients who did not stop smoking.
Within about 2 or 3 months, she had necrotic toes on her
other foot, which were then treated with gene therapy
successfully.
I thank you again for your comments.
Dr Peter J. Pappas (Newark, NJ). In working with
DNA and RNA, one of the things I have learned is that if
you breathe on these substances, they degrade. What I do
not understand is how naked plasmid DNA injected into
the muscle can somehow evade the body’s own DNAases
and RNAases? What is it about this intramuscular injection
that allows it to incorporate into the muscle’s own nuclear
structure and yet evade breakdown?
Dr Symes. We have looked at the pathologic specimens
on a couple of patients who have had amputations. We
have seen evidence of broken bits of plasmid in the tissues
in and around the injection sites, but presumably enough
of the DNA does get incorporated into the cells to pro-
duce a meaningful biologic effect.
Dr Pappas. It is just difficult for me to comprehend
this, because even in the animal studies with adenoviral
vectors, where you can look at protein expression and
gene expression, you only get a response for up to 3 weeks
and then the body attacks the vector and treats it like a for-
eign substance. I just cannot comprehend how this works,
if it does work.
Dr Symes. Our studies also indicate VEGF production
for up to 3 weeks, and it is for that reason that we repeat
the gene transfection, administering a second dose 4
weeks after the first.
Dr Frank J. Veith (Bronx, NY). I think many of us are
skeptical. Even though 1 of the patients you showed was
our patient, and I agree it was a dramatic response, I think
that before we are going to accept the hypothesis as
proven, we would like to see some kind of controlled
study. All of us have had the experience of seeing a patient
who has had multiple previous failures with extensive
ulceration and gangrene and who refuses amputation, and,
lo and behold, after 6 months they come back healed.
Maybe it occurs for other reasons. Thus, before we accept
this, there should be a randomized, prospective study. I
wonder if you are planning such a study or at least some
kind of controlled study?
Dr Symes. I totally agree with you, and frankly, I was
probably as skeptical as anyone that there would be any
benefit when this study was started. In the laboratory, we
can get dramatic improvement in rabbits and rats and
impressive evidence of stimulation of angiogenesis.
However, these patients are end-stage. The thought that
putting a little DNA into these legs would produce a ben-
eficial effect is good reason for skepticism.
I agree that to prove the therapy you need a random-
ized trial as you do for any new therapy, and ultimately this
will need to be done.
At this point, I think we still need to refine the therapy
to the point where we are absolutely convinced that we are
seeing a strong biologic effect under all circumstances. The
purpose of this phase I trial was really to try to bring a new
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therapeutic concept to the clinic. It will be a few years before
this is something that will be an alternative in the routine
treatment of patients with peripheral vascular disease.
Dr K. Craig Kent (New York, NY). I share Dr Veith’s
skepticism. It is certainly going to take time before we sort
out all of this. You noticed that there was an increase in
the ankle brachial indices of 0.1 in these patients. What do
you think the error of that test is? Do you really think that
0.1 is a significant increase in circulation in these patients?
You noticed a great deal of edema. In some of these
patients were you worried about a compartment syn-
drome? Is this something that we need to consider?
And my third question is, how did you decide where
to do the injections? Were they truly random, or did you
have some pattern? There is a great deal of muscle in the
thigh and the calf, and it would seem that you would have
to have had some pattern of injection to be able to con-
nect the collaterals.
Dr Symes. Unfortunately, the ankle brachial index is
not an effective way to show increased angiogenesis at the
microvascular level. I can tell you that in conducting the
trial, we have attempted to carry out these noninvasive
studies as meticulously as possible. We document it twice
before starting the therapy. I think any change that you see
is as real as it can be. If you use the standard criteria that
a change of greater than 0.1 or 0.15 implies some kind of
significant change in the circulation, then in some of these
patients we have seen increases of 0.2 or 0.3. However, I
think it is a gross way to measure what is going on here
and probably is not going to show us a great deal.
The edema was a concern. Compartment syndrome was
not seen in any of these patients. We did treat them fairly
aggressively when we had the opportunity to detect the
edema early. Once we recognized it in a couple of the early
patients, the patients were told that if leg swelling developed
they were to get back to us right away and they were put on
diuretics. It is transient and goes away within 1 to 2 weeks.
In terms of where we inject the gene, our concept was
2-fold. First, we had to inject it into viable muscle.
Second, hypoxic muscle might be a better site for VEGF
to exert its effect because of the upregulation of the recep-
tors in that setting. So, we have tended, as the study has
gone along, to try to administer it further distally in the
limb and even have tried to administer it down near the
foot level in a couple of patients.
Dr Theresa Jacob (Brooklyn, NY). I enjoyed your pre-
sentation, and I have a few questions for you.
My first concern relates to your bioreactivity studies.
Was the VEGF gene or its product detected at 8 weeks?
Were long-term time course experiments for VEGF gene
expression performed? Because you have used the transfer
of naked DNA, we would like to know the duration of this
expression in the vascular tissues. At Maimonides Medical
Center, we studied the bioreactivity of the p53 gene in a
rat carotid injury model, and we observed a limited life
span of this transfected gene. However, its expression
could be prolonged by the use of selective immunosup-
pression with CTLA4Ig.
The other question is regarding the amputated limb.
Did you do any in situ hybridization tests or immunohis-
tochemical studies on that amputated limb? What were the
results? Could you detect the VEGF DNA sequence or
localize its expression in any of the tissues?
Dr Symes. Actually the answers to both questions are
similar. Our studies in the laboratory and in the patients that
measured the VEGF protein levels have documented that
most of the gene that is produced is produced between 1
and 3 weeks and that when you get out to 4 weeks the gene
is no longer producing protein. The one amputation speci-
men was obtained from an amputation that occurred about
3 months after the gene injection, so we were not able to
document any evidence of protein expression at that time.
Dr Michael A. Golden (Philadelphia, Pa). I enjoyed
your presentation and feel that there is great promise with
this. I have just a few questions for you.
You had mentioned earlier in answer to someone’s ques-
tion that you saw some DNA. Was that in one of your ani-
mal models where you biopsied the muscle, or was it an
amputated limb? Is there any evidence of muscle necrosis or
inflammatory response? What is the size of the material that
you are injecting? Obviously, you have a promoter/enhancer
construct to drive expression. You should be able to identify
that if you looked for it. Have you looked for it?
Dr Symes. Yes, and indeed we have seen it. We use a
cytomegalo-virus promoter/enhancer. The pieces of plasmid
that I mentioned we saw were in the amputated specimen
near the sites of injection of the DNA. There was no evidence
of any muscle necrosis. We did serial creatine phosphokinase
measurements on these patients and found no increase in cre-
atine phosphokinase. The patients noticed some mild dis-
comfort near the injection sites in a few instances, but there
was no gross inflammatory response evident.
Dr Golden. Was there pulmonary edema or any prob-
lem with edema elsewhere?
Dr Symes. No.
Dr Golden. So, you would find edema in the con-
tralateral leg but in no other organs?
Dr Symes. We did see a little edema in the contralateral
leg on occasion, but that is the only other place we saw it.
Dr Maciej Dryjski (Buffalo, NY). Have you seen any
difference in the VEGF level among the patients who fail
therapy and among those who improved?
Dr Symes. No. The transient increase in VEGF levels is
highly variable. The manuscript includes a table that shows
all of the individual measurements. You will note that
there is a great deal of variability from patient to patient.
The only pattern that we saw was this biphasic peak that
occurred 1 to 3 weeks after each injection. I think that is
partly because of the timing of when the sample was taken
(once per week). So, one could miss the peak value in 1
patient and hit it in another, but there certainly was a good
deal of variability between patients.
